CD38 and Miyoshi myopathy: The current standard-of-care (SOC) for newly diagnosed (NDMM) and relapsed (MMRR) MM patients includes monoclonal antibodies targeting the NAD+-degrading enzyme CD38, thus supporting dependence on a sustained NAD+ biosynthesis also for this tumor [15,16,17,18,19,20].